Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 1,000

Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins
Bui, J. D., Uppaluri, R., Hsieh, C., & Schreiber, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0556 · Cited by 102
Regulatory T cells and tumour immunity – observations in mice and men
Gallimore, A., & Godkin, A. J. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02748.x · Cited by 101
Vaccine therapy for melanoma: Current status and future directions
Terando, A. M., Faries, M. B., & Morton, D. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.033 · Cited by 100
Cancer Immunoediting in Malignant Glioma
Dunn, G. P., Fecci, P. E., & Curry, W. T. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31824f840d · Cited by 99
Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer
Yamamoto, T., Yanagimoto, H., Satoi, S., Toyokawa, H., Hirooka, S., Yamaki, S., Yui, R., Yamao, J., Kim, S., & Kwon, A. (2011) · Pancreas · doi:10.1097/mpa.0b013e3182373a66 · Cited by 98
Immunotherapy of malignant brain tumors
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00603.x · Cited by 99
Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration
Karavitis, J., Hix, L. M., Shi, Y. H., Schultz, R. F., Khazaie, K., & Zhang, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046342 · Cited by 98
Human Dendritic Cell Subsets for Vaccination
Dubsky, P. C., Ueno, H., Piqueras, B., Connolly, J., Banchereau, J., & Palucka, K. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-8216-7 · Cited by 100
Current concepts of tumor-infiltrating lymphocytes in human malignancies
Chiou, S., Sheu, B., Chang, W., Huang, S., & Ho, H. (2005) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2005.06.002 · Cited by 100
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · BioMed Research International · doi:10.1155/2012/926321 · Cited by 103
Effective Cancer Therapy Through Immunomodulation
Waldmann, T. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104549 · Cited by 97
TGF-beta as a T cell regulator in colitis and colon cancer
Becker, C., Fantini, M. C., & Neurath, M. F. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.004 · Cited by 98
Myeloid Suppressor Cells and Immune Modulation in Lung Cancer
Srivastava, M. K., Andersson, Å., Zhu, L. X., Harris‐White, M. E., Lee, J. M., Dubinett, S. M., & Sharma, S. P. (2012) · Immunotherapy · doi:10.2217/imt.11.178 · Cited by 95
T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?
Anzengruber, F., Avci, P., de Freitas, L. F., & Hamblin, M. R. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00455h · Cited by 97
The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/430394 · Cited by 98
The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Basudan, A. (2022) · Clinics and Practice · doi:10.3390/clinpract13010003 · Cited by 99
Donor Lymphocyte Infusions to Treat Hematologic Malignancies in Relapse after Allogeneic Blood or Marrow Transplantation
Luznik, L., & Fuchs, E. J. (2002) · Cancer Control · doi:10.1177/107327480200900205 · Cited by 95
Stat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 94
T Regulatory Cells in Allergy and Health: A Question of Allergen Specificity and Balance
Taylor, A., Verhagen, J., Akdiş, C. A., & Akdiş, M. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000080523 · Cited by 93
Combined chemoimmunotherapy of solid tumours: Improving vaccines?
Nowak, A. K., Lake, R., & Robinson, B. W. S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.04.002 · Cited by 94
Reversal of Tumor-Mediated Immunosuppression
Vieweg, J., Su, Z. Z., Dahm, P., & Kusmartsev, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1924 · Cited by 92
Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Tuve, S., Chen, B., Liu, Y., Cheng, T., Touré, P. S., Sow, P. S., Feng, Q., Kiviat, N., Strauss, R., Ni, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4296 · Cited by 92
The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells
François, V., Ottaviani, S., Renkvist, N., Stockis, J., Schuler, G., Thielemans, K., Colau, D., Marchand, M., Boon, T., Lucas, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3726 · Cited by 90
Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate‐pulsed dendritic cells in a murine glioma model
Grauer, O. M., Sutmuller, R. P. M., van Maren, W. W. C., Jacobs, J. F. M., Bennink, E. J., Toonen, L. W. J., Nierkens, S., & Adema, G. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.23284 · Cited by 90
Self-citation
Notch2 Signaling Is Required for Potent Antitumor Immunity In Vivo
Sugimoto, K., Maekawa, Y., Kitamura, A., Nishida, J., Koyanagi, A., Yagita∥, H., Kojima, H., Chiba, S., Shimada, M., & Yasutomo, K. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903661 · Cited by 93
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Heimberger, A. B., & Sampson, J. H. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903124346 · Cited by 89
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Kline, J. P., Brown, I. E., Zha, Y.-Y., Blank, C. U., Strickler, J. H., Wouters, H., Zhang, L., & Gajewski, T. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4696 · Cited by 89
Colon cancer and the immune system: The role of tumor invading T cells
Waldner, M. J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i45.7233 · Cited by 92
Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13
Park, J. M., Terabe, M., van den Broeke, L. T., Donaldson, D. D., & Berzofsky, J. A. (2004) · International Journal of Cancer · doi:10.1002/ijc.20669 · Cited by 88
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 87
The Role of Non-Deletional Tolerance Mechanisms in a Murine Model of Mixed Chimerism with Costimulation Blockade
Bigenzahn, S., Blaha, P., Koporc, Z., Pree, I., Selzer, E., Bergmeister, H., Wrba, F., Heusser, C., Wagner, K., Muehlbacher, F., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00862.x · Cited by 87
Comparative methodologies of regulatory T cell depletion in a murine melanoma model
Matsushita, N., Pilon‐Thomas, S., Martin, L. M., & Riker, A. I. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.012 · Cited by 89
Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma
Redman, B. G., Chang, A. E., Whitfield, J. R., Esper, P., Jiang, G., Braun, T., Roessler, B. J., & Mulé, J. J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817fd90b · Cited by 87
Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity
Perret, R., Sierro, S. R., Botelho, N. K., Corgnac, S., Donda, A., & Romero, P. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0875 · Cited by 85
Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
T-Bet Plays a Key Role in NK-Mediated Control of Melanoma Metastatic Disease
Werneck, M. B. F., Lugo‐Villarino, G., Hwang, E. S., Cantor, H., & Glimcher, L. H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8004 · Cited by 84
Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Nishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J., & Shiku, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5839 · Cited by 84
Peripheral Generation and Function of CD4+CD25+ Regulatory T Cells
Taams, L. S., & Akbar, A. N. (2005) · Springer eBooks · doi:10.1007/3-540-27702-1_6 · Cited by 84
The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established Tumors
Kudo‐Saito, C., Schlom, J., Camphausen, K. A., Coleman, C. N., & Hodge, J. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2237 · Cited by 84
Immune checkpoint modulation: Rational design of combination strategies
Zamarin, D., & Postow, M. A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.003 · Cited by 85
Integrated cancer tissue engineering models for precision medicine
Bregenzer, M. E., Horst, E. N., Mehta, P., Novak, C. M., Raghavan, S. A., Snyder, C. S., & Mehta, G. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216564 · Cited by 84
Vaccination for Treatment and Prevention of Cancer in Animal Models
Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G., & Melief, C. J. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90005-4 · Cited by 83
Self-citation
Regulatory T cells and tumor immunity
Chattopadhyay, S., Chakraborty, N. G., & Mukherji, B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0699-9 · Cited by 83
Increased Expression of CTLA-4 in Malignant T Cells from Patients with Mycosis Fungoides – Cutaneous T-Cell Lymphoma
Wong, H. K., Wilson, A. J., Gibson, H. M., Hafner, M. S., Hedgcock, C. J., Berger, C. L., Edelson, R. L., & Lim, H. W. (2005) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700029 · Cited by 83
Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
Ma, J., Urba, W. J., Si, L., Wang, Y., Fox, B. A., & Hu, H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324034 · Cited by 82
Induction of Postsurgical Tumor Immunity and T-Cell Memory by a Poorly Immunogenic Tumor
Zhang, P., Côté, A. L., de Vries, V. C., Usherwood, E. J., & Turk, M. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1264 · Cited by 81
CD4+CD25+‐Regulatory T Cells from Mouse to Man
Wing, K., Suri‐Payer, E., & Rudin, A. (2005) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2005.01634.x · Cited by 80
Cytotoxic T Lymphocyte Antigen-4 Gene in Breast Cancer
Ghaderi, A. A., Yeganeh, F., Kalantari, T., Talei, A., Pezeshki, A. M., Doroudchi, M., & Dehaghani, A. S. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000032918.89120.8e · Cited by 79
Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells
Shafer-Weaver, K., Anderson, M. J. M., Stagliano, K. E., Malyguine, A. M., Greenberg, N. M., & Hurwitz, A. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900848 · Cited by 79
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
Linch, S. N., Kasiewicz, M. J., McNamara, M. J., Hilgart-Martiszus, I., Farhad, M. E., & Redmond, W. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510518113 · Cited by 79
Intra-tumoural regulatory T cells: A potential new target in cancer immunotherapy
Needham, D. J., Lee, J. X., & Beilharz, M. W. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.018 · Cited by 79
Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
Fan, Y., Du, R., Wei, F., Zhao, H., Yu, J., Wang, C., Zhan, Z., Ding, T., Ren, X., Chen, X., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1751-z · Cited by 78
Dendritic Cells in Cancer Immunotherapy
Vulink, A. J. E., Radford, K. J., Melief, C. J. M., & Hart, D. N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(07)99006-5 · Cited by 80
Self-citation
The significance of Treg cells in defective tumor immunity
Kosmaczewska, A., Ciszak, L., Potoczek, S., & Frydecka, I. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0018-1 · Cited by 78
Tuning tumor-specific T-cell activation: a matter of costimulation?
Abken, H., Hombach, A. A., Heuser, C., Kronfeld, K., & Seliger, B. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02180-4 · Cited by 78
Regulation of tumour immunity by CD25+ T cells
Gallimore, A., & Sakaguchi, S. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01471.x · Cited by 78
Enhancement of T-cell–Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer
Dings, R. P. M., Vang, K. B., Castermans, K., Popescu, F. E., Zhang, Y., Egbrink, M. G. A. O., Mescher, M. F., Farrar, M. A., Griffioen, A. W., & Mayo, K. H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2443 · Cited by 77
Cancer immunotherapy
Gajewski, T. F. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.002 · Cited by 79
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
Hooijkaas, A. I., Gadiot, J., Morrow, M., Stewart, R. A., Schumacher, T. N., & Blank, C. U. (2012) · OncoImmunology · doi:10.4161/onci.20226 · Cited by 75
Self-citation
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
Sharma, N., Vacher, J., & Allison, J. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819004116 · Cited by 75
Self-citation
Rational combinations of immunotherapeutics that target discrete pathways
Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 77
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment
Jin, Y., An, X., Mao, B., Sun, R., Kumari, R., Chen, X., Shan, Y., Zang, M., Xu, L., Muntel, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07153-z · Cited by 73
Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity
Radosavljevic, G. D., Jovanović, I., Majstorović, I., Mitrović, M., Lisnić, V. J., Arsenijević, N., Jonjić, S., & Lukić, M. L. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9383-y · Cited by 73
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
Boasberg, P. D., Hamid, O., & O'Day, S. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.004 · Cited by 73
Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells
Pruitt, S. K., Boczkowski, D., de Rosa, N., Haley, N. R., Morse, M. A., Tyler, D. S., Dannull, J., & Nair, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141383 · Cited by 75
Tumor Cell Loaded Type-1 Polarized Dendritic Cells Induce Th1-Mediated Tumor Immunity
Hokey, D. A., Larregina, A. T., Erdös, G., Watkins, S. C., & Falo, L. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1692 · Cited by 74
Curcumin as an Adjuvant to Cancer Immunotherapy
Paul, S., & Sa, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675923 · Cited by 74
Regulatory T cells and toll-like receptors: regulating the regulators
Sutmuller, R. P. M., Garritsen, A., & Adema, G. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.078535 · Cited by 72
Self-citation
Immunotherapy as part of combinations for the treatment of cancer
Mitchell, M. S. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(03)00019-5 · Cited by 72
Innate Immune Recognition and Suppression of Tumors
Hayakawa, Y., & Smyth, M. J. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95008-8 · Cited by 71
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Rivoltini, L., Canese, P., Huber, V., Iero, M., Pilla, L., Valenti, R., Fais, S., Lozupone, F., Casati, C., Castelli, C., et al. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.463 · Cited by 74
Anti-CTLA-4 treatment induces IL-10-producing ICOS + regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis
Coquerelle, C., Oldenhove, G., Acolty, V., Denoeud, J., Vansanten, G., Verdebout, J., Mellor, A. L., Bluestone, J. A., & Moser, M. (2009) · Gut · doi:10.1136/gut.2008.162842 · Cited by 71
Enhancing immune responses to tumor-associated antigens
Higgins, J. P., Bernstein, M. B., & Hodge, J. W. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.15.9133 · Cited by 77
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer
Zabala, M., Lasarte, J. J., Perret, C., Sola, J., Berraondo, P., Alfaro, M., Larrea, E., Prìeto, J., & Kramer, M. G. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.07.025 · Cited by 71
Cutting Edge: Lipopolysaccharide Induces IL-10-Producing Regulatory CD4+ T Cells That Suppress the CD8+ T Cell Response
den Haan, J. M. M., Kraal, G., & Bevan, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5429 · Cited by 72
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
Charalambous, A., Oks, M., Nchinda, G., Yamazaki, S., & Steinman, R. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8410 · Cited by 71
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer
Brooks, J., Fleischmann-Mundt, B., Woller, N., Niemann, J., Ribback, S., Peters, K., Demir, İ. E., Armbrecht, N., Ceyhan, G. O., Manns, M. P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2415 · Cited by 70
Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells
Cao, M., Cabrera, R., Xu, Y., Firpi, R. J., Zhu, H., Liu, C., & Nelson, D. R. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700540 · Cited by 69
Genes of tolerance
Akdiş, C. A., Blaser, K., & Akdiş, M. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00587.x · Cited by 69
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 73
Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations
Lesterhuis, W. J., Rinaldi, C., Jones, A. C., Rozali, E. N., Dick, I. M., Khong, A., Boon, L., Robinson, B. W. S., Nowak, A. K., Bosco, A., et al. (2015) · Scientific Reports · doi:10.1038/srep12298 · Cited by 69
Timed Ablation of Regulatory CD4+ T Cells Can Prevent Murine AIDS Progression
Beilharz, M. W., Sammels, L. M., Paun, A., Shaw, K., van Eeden, P. E., Watson, M. W., & Ashdown, M. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4917 · Cited by 68
Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?
Antony, P. A., & Restifo, N. P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00002 · Cited by 68
Endogenous Retrovirus Expression Is Required for Murine Melanoma Tumor Growth In vivo
Mangeney, M., Pothlichet, J., Renard, M., Ducos, B., & Heidmann, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4231 · Cited by 68
Effects of interleukin 4 on CD25+CD4+ regulatory T cell function
Maerten, P., Shen, C., Bullens, D. M. A., Assche, G. V., Gool, S. V., Geboes, K. J., Rutgeerts, P. J., & Ceuppens, J. L. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.04.001 · Cited by 68
Immunotherapy of Malignant Diseases
Ko, E. C., Wang, X., & Ferrone, S. (2003) · International Archives of Allergy and Immunology · doi:10.1159/000074897 · Cited by 68
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 73
Combination of CTL-associated Antigen-4 Blockade and Depletion of CD25+Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell-based Vaccine in a Mouse Model of Colon Cancer
Saha, A., & Chatterjee, S. K. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02355.x · Cited by 67
The impact of regulatory T cells on carcinogen-induced sarcogenesis
Betts, G. J., Twohig, J. P., van den Broek, M. F., Sierro, S. R., Godkin, A. J., & Gallimore, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603824 · Cited by 71
Regulatory T cell: a protection for tumour cells
Wang, Y., Ma, Y., Fang, Y., Wu, S., Liu, L., Fu, D., & Shen, X. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01437.x · Cited by 67
Association of CTLA‐4 gene polymorphism with oral squamous cell carcinoma
Wong, Y. K., Chang, K., Cheng, C., & Liu, C. ‐. (2005) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2005.00377.x · Cited by 67
Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma
Chu, Y., Wang, L.-X., Yang, G., Ross, H. J., Urba, W. J., Prell, R. A., Jooss, K. U., Xiong, S., & Hu, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199198.43587.ba · Cited by 69
Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines
Rüter, J. (2009) · Frontiers in bioscience · doi:10.2741/3338 · Cited by 66
Transplantation tolerance: lessons from experimental rodent models
Kingsley, C. I., Nadig, S. N., & Wood, K. J. (2007) · Transplant International · doi:10.1111/j.1432-2277.2007.00533.x · Cited by 66
TLR2-Dependent Induction of IL-10 and Foxp3+CD25+CD4+ Regulatory T Cells Prevents Effective Anti-Tumor Immunity Induced by Pam2 Lipopeptides In Vivo
Yamazaki, S., Okada, K., Maruyama, A., Matsumoto, M., Yagita∥, H., & Seya, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018833 · Cited by 66
Partial Reduction of Human FOXP3+ CD4 T Cells In Vivo After CD25-directed Recombinant Immunotoxin Administration
Powell, D. J., Attia, P., Ghetie, V. F., Schindler, J. D., Vitetta, E. S., & Rosenberg, S. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31815dc0e8 · Cited by 66
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
Gattinoni, L., Ranganathan, A., Surman, D. R., Palmer, D. C., Antony, P. A., Theoret, M. R., Heimann, D. M., Rosenberg, S. A., & Restifo, N. P. (2006) · Blood · doi:10.1182/blood-2006-07-034066 · Cited by 65
Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L
Calmels, B., Paul, S., Futin, N., Ledoux, C., Stoeckel, F., & Acres, B. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700781 · Cited by 65
Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinoma
Yoshioka, T., Miyamoto, M., Cho, Y., Ishikawa, K., Tsuchikawa, T., Kadoya, M., Li, L., Mishra, R., Ichinokawa, K., Shoji, Y., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604294 · Cited by 65
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer
Lavoué, V., Thedrez, A., Lévêque, J., Foucher, F., Henno, S., Jauffret, V., Belaud‐Rotureau, M., Catros, V., & Cabillic, F. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-147 · Cited by 64

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks